Targeting protein-protein interactions (PPIs) of transcription factors: Challenges of intrinsically disordered proteins (IDPs) and regions (IDRs)

Progress in Biophysics and Molecular Biology

Volumn 119, Issue 1, 2015, Pages 41-46

  Sammak, Susan ^a   Zinzalla, Giovanna ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anticancer therapy; C MYC; HIF 1; Intrinsically disordered proteins; Protein protein interactions; STAT3; Transcription factors; catenin

Indexed keywords

INTRINSICALLY DISORDERED PROTEIN; PROTEIN BINDING; TRANSCRIPTION FACTOR;

ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; PROCEDURES;

ANIMALS; DRUG DISCOVERY; HUMANS; INTRINSICALLY DISORDERED PROTEINS; PROTEIN BINDING; TRANSCRIPTION FACTORS;

EID: 84940894514     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2015.06.004     Document Type: Review

References (77)

1. Avendaño C., Menéndez J. Peptidomimetics in cancer chemotherapy. Clin. Transl. Oncol. 2007, 9:563-570.
2. Babu M.M., van der Lee R., de Groot N.S., Gsponer J. Intrinsically disordered proteins: regulation and disease. Curr. Opin. Struct. Biol. 2011, 21:432-440.
3. Bagnasco L., Tortolina L., Biasotti B., Castagnino N., Ponassi R., Tomati V., Nieddu E., Stier G., Malacarne D., Parodi S. Inhibition of a protein-protein interaction between INI1 and c-Myc by small peptidomimetic molecules inspired by Helix-1 of c-Myc: identification of a new target of potential antineoplastic interest. FASEB J. 2007, 21:1256-1263.
4. Barnard A., Long K., Martin H.L., Miles J.A., Edwards T.A., Tomlinson D.C., Macdonald A., Wilson A.J. Selective and potent proteomimetic inhibitors of intracellular Protein-Protein interactions. Angew. Chem. Int. Ed. 2015, 54:2960-2965.
5. Brown C.J., Quah S.T., Jong J., Goh A.M., Chiam P.C., Khoo K.H., Choong M.L., Lee M.A., Yurlova L., Zolghadr K., Joseph T.L., Verma C.S., Lane D.P. Stapled peptides with improved potency and specificity that activate p53. ACS Chem. Biol. 2013, 8:506-512.
6. Burslem G.M., Kyle H.F., Breeze A.L., Edwards T.A., Nelson A., Warriner S.L., Wilson A.J. Small-molecule proteomimetic inhibitors of the HIF-1alpha-p300 protein-protein interaction. Chembiochem 2014, 15:1083-1087.
7. Buscarlet M., Krasteva V., Ho L., Simon C., Hebert J., Wilhelm B., Crabtree G.R., Sauvageau G., Thibault P., Lessard J.A. Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. Blood 2014, 123:1720-1728.
8. Cheng S.W., Davies K.P., Yung E., Beltran R.J., Yu J., Kalpana G.V. c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat. Genet. 1999, 22:102-105.
9. Cheng Y., Oldfield C.J., Meng J., Romero P., Uversky V.N., Dunker A.K. Mining α-Helix-forming molecular recognition features with cross species sequence alignments†. Biochemistry 2007, 46:13468-13477.
10. Choi H., Chun Y.-S., Kim S.-W., Kim M.-S., Park J.-W. Curcumin inhibits hypoxia-inducible Factor-1 by Degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol. Pharmacol. 2006, 70:1664-1671.
11. Clevers H. Wnt/β-Catenin signaling in development and disease. Cell. 2006, 127:469-480.
12. Darnell J.E. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2:740-749.
13. Dhanik A., McMurray J.S., Kavraki L.E. Binding modes of peptidomimetics designed to inhibit STAT3. PLoS One 2012, 7:e51603.
14. Dharanipragada R. New modalities in conformationally constrained peptides for potency, selectivity and cell permeation. Future Med. Chem. 2013, 5:831-849.
15. Driggers E.M., Hale S.P., Lee J., Terrett N.K. The exploration of macrocycles for drug discovery [mdash] an underexploited structural class. Nat. Rev. Drug Discov. 2008, 7:608-624.
16. Dunker A.K., Uversky V.N. Drugs for 'protein clouds': targeting intrinsically disordered transcription factors. Curr. Opin. Pharmacol. 2010, 10:782-788.
17. Ecevit O., Khan M.A., Goss D.J. Kinetic analysis of the interaction of b/HLH/Z transcription factors Myc, Max, and Mad with cognate DNA. Biochemistry 2010, 49:2627-2635.
18. Fagard R., Metelev V., Souissi I., Baran-Marszak F. STAT3 inhibitors for cancer therapy: have all roads been explored?. JAK-STAT 2013, 2:e22882.
19. Fasolini M., Wu X., Flocco M., Trosset J.Y., Oppermann U., Knapp S. Hot spots in Tcf4 for the interaction with beta-catenin. J. Biol. Chem. 2003, 278:21092-21098.
20. Follis A.V., Hammoudeh D.I., Daab A.T., Metallo S.J. Small-molecule perturbation of competing interactions between c-Myc and Max. Bioorg. Med. Chem. Lett. 2009, 19:807-810.
21. Follis A.V., Hammoudeh D.I., Wang H., Prochownik E.V., Metallo S.J. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem. Biol. 2008, 15:1149-1155.
22. Furqan M., Akinleye A., Mukhi N., Mittal V., Chen Y., Liu D. STAT inhibitors for cancer therapy. J. Hematol. Oncol. 2013, 6:90.
23. Gonsalves F.C., Klein K., Carson B.B., Katz S., Ekas L.A., Evans S., Nagourney R., Cardozo T., Brown A.M., DasGupta R. An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway. Proc. Natl. Acad. Sci. U S A 2011, 108:5954-5963.
24. Groner B., Weber A., Mack L. Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors. Bioengineered 2012, 3:320-325.
25. Grossmann T.N., Yeh J.T.-H., Bowman B.R., Chu Q., Moellering R.E., Verdine G.L. Inhibition of oncogenic Wnt signaling through direct targeting of β-catenin. Proc. Natl. Acad. Sci. 2012, 109:17942-17947.
26. Haftchenary S., Luchman H.A., Jouk A.O., Veloso A.J., Page B.D.G., Cheng X.R., Dawson S.S., Grinshtein N., Shahani V.M., Kerman K., Kaplan D.R., Griffin C., Aman A.M., Al-awar R., Weiss S., Gunning P.T. Potent targeting of the STAT3 protein in Brain Cancer stem cells: a promising route for treating glioblastoma. ACS Med. Chem. Lett. 2013, 4:1102-1107.
27. Hammoudeh D.I., Follis A.V., Prochownik E.V., Metallo S.J. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J. Am. Chem. Soc. 2009, 131:7390-7401.
28. Harvey S.R., Porrini M., Stachl C., MacMillan D., Zinzalla G., Barran P.E. Small-molecule inhibition of c-MYC: MAX leucine zipper formation is revealed by ion mobility mass spectrometry. J. Am. Chem. Soc. 2012, 134:19384-19392.
29. Hruby V.J., Cai M. Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles. Annu Rev. Pharmacol. Toxicol. 2013, 53:557-580.
30. Huang Z., Zhang M., Burton S.D., Katsakhyan L.N., Ji H. Targeting the Tcf4 G13ANDE17 binding site to selectively disrupt beta-catenin/T-cell factor protein-protein interactions. ACS Chem. Biol. 2014, 9:193-201.
31. Kung A.L., Zabludoff S.D., France D.S., Freedman S.J., Tanner E.A., Vieira A., Cornell-Kennon S., Lee J., Wang B., Wang J., Memmert K., Naegeli H.U., Petersen F., Eck M.J., Bair K.W., Wood A.W., Livingston D.M. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell. 2004, 6:33-43.
32. Kushal S., Lao B.B., Henchey L.K., Dubey R., Mesallati H., Traaseth N.J., Olenyuk B.Z., Arora P.S. Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling. Proc. Natl. Acad. Sci. U S A 2013, 110:15602-15607.
33. Kwon H.S., Kim D.R., Yang E.G., Park Y.K., Ahn H.C., Min S.J., Ahn D.R. Inhibition of VEGF transcription through blockade of the hypoxia inducible factor-1alpha-p300 interaction by a small molecule. Bioorg. Med. Chem. Lett. 2012, 22:5249-5252.
34. Lao B.B., Drew K., Guarracino D.A., Brewer T.F., Heindel D.W., Bonneau R., Arora P.S. Rational design of topographical helix mimics as potent inhibitors of protein-protein interactions. J. Am. Chem. Soc. 2014, 136:7877-7888.
35. Lee Tong I., Young Richard A. Transcriptional regulation and its misregulation in disease. Cell 2013, 152:1237-1251.
36. Lepourcelet M., Chen Y.N., France D.S., Wang H., Crews P., Petersen F., Bruseo C., Wood A.W., Shivdasani R.A. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004, 5:91-102.
37. McMurray J.S., Mandal P.K., Liao W.S., Klostergaard J., Robertson F.M. The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain. JAKSTAT 2012, 1:263-347.
38. Metallo S.J. Intrinsically disordered proteins are potential drug targets. Curr. Opin. Chem. Biol. 2010, 14:481-488.
39. Metallo S.J. Intrinsically disordered proteins are potential drug targets. Curr. Opin. Chem. Biol. 2010, 14:481-488.
40. Minezaki Y., Homma K., Kinjo A.R., Nishikawa K. Human transcription factors contain a high fraction of intrinsically disordered regions essential for transcriptional regulation. J. Mol. Biol. 2006, 359:1137-1149.
41. Monti E., Gariboldi M.B. HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr. Mol. Pharmacol. 2011, 4:62-77.
42. Morton J.P., Sansom O.J. MYC-y mice: from tumour initiation to therapeutic targeting of endogenous MYC. Mol. Oncol. 2013, 7:248-258.
43. Mullard A. Protein-protein interaction inhibitors get into the groove. Nat. Rev. Drug Discov. 2012, 11:173-175.
44. Nair S.K., Burley S.K. X-Ray structures of Myc-Max and Mad-Max recognizing DNA. Cell 2003, 112:193-205.
45. Nero T.L., Morton C.J., Holien J.K., Wielens J., Parker M.W. Oncogenic protein interfaces: small molecules, big challenges. Nat. Rev. Cancer 2014, 14:248-262.
46. Pescarolo M.P., Bagnasco L., Malacarne D., Melchiori A., Valente P., Millo E., Bruno S., Basso S., Parodi S. A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems. FASEB J. 2001, 15:31-33.
47. Polakis P. Wnt signaling in Cancer. Cold Spring Harb. Perspect. Biol. 2012, 4.
48. Poy F., Lepourcelet M., Shivdasani R.A., Eck M.J. Structure of a human Tcf4-beta-catenin complex. Nat. Struct. Biol. 2001, 8:1053-1057.
49. Prochownik E.V., Vogt P.K. Therapeutic targeting of Myc. Gene Cancer 2010, 6:650-659.
50. Redell M.S., Tweardy D.J. Targeting transcription factors for cancer therapy. Curr. Pharm. Des. 2005, 11:2873-2887.
51. Reece K., Richardson E., Cook K., Campbell T., Pisle S., Holly A., Venzon D., Liewehr D., Chau C., Price D., Figg W. Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1alpha/p300 complex in a preclinical model of prostate cancer. Mol. Cancer 2014, 13:91.
52. Rogers J.M., Oleinikovas V., Shammas S.L., Wong C.T., De Sancho D., Baker C.M., Clarke J. Interplay between partner and ligand facilitates the folding and binding of an intrinsically disordered protein. Proc. Natl. Acad. Sci. 2014, 111:15420-15425.
53. Savino M., Annibali D., Carucci N., Favuzzi E., Cole M.D., Evan G.I., Soucek L., Nasi S. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One 2011, 6:e22284.
54. Semenza G.L. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci. STKE 2007, 2007. cm8.
55. Showalter S.A. Intrinsically disordered proteins: methods for structure and dynamics studies, eMagRes 2014, John Wiley & Sons, Ltd.
56. Siveen K.S., Sikka S., Surana R., Dai X., Zhang J., Kumar A.P., Tan B.K.H., Sethi G., Bishayee A. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochimica Biophysica Acta (BBA) - Rev. Cancer 2014, 1845:136-154.
57. Soucek L., Whitfield J., Martins C.P., Finch A.J., Murphy D.J., Sodir N.M., Karnezis A.N., Swigart L.B., Nasi S., Evan G.I. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455:679-683.
58. Stojanova A., Penn L.Z. The role of INI1/hSNF5 in gene regulation and cancer. Biochem. Cell. Biol. 2009, 87:163-177.
59. Sugase K., Dyson H.J., Wright P.E. Mechanism of coupled folding and binding of an intrinsically disordered protein. Nature 2007, 447:1021-1025.
60. Sun H.L., Liu Y.N., Huang Y.T., Pan S.L., Huang D.Y., Guh J.H., Lee F.Y., Kuo S.C., Teng C.M. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene 2007, 26:3941-3951.
61. Tian W., Han X., Yan M., Xu Y., Duggineni S., Lin N., Luo G., Li Y.M., Huang Z., An J. Structure-based discovery of a novel inhibitor targeting the beta-catenin/Tcf4 interaction. Biochemistry 2012, 51:724-731.
62. Trosset J.Y., Dalvit C., Knapp S., Fasolini M., Veronesi M., Mantegani S., Gianellini L.M., Catana C., Sundstrom M., Stouten P.F., Moll J.K. Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins 2006, 64:60-67.
63. Tu W.B., Helander S., Pilstål R., Hickman K.A., Lourenco C., Jurisica I., Raught B., Wallner B., Sunnerhagen M., Penn L.Z. Myc and its interactors take shape. Biochimica Biophysica Acta (BBA) - Gene Regul. Mech. 2014.
64. Vagner J., Qu H., Hruby V.J. Peptidomimetics, a synthetic tool of drug discovery. Curr. Opin. Chem. Biol. 2008, 12:292-296.
65. van der Lee R., Buljan M., Lang B., Weatheritt R.J., Daughdrill G.W., Dunker A.K., Fuxreiter M., Gough J., Gsponer J., Jones D.T., Kim P.M., Kriwacki R.W., Oldfield C.J., Pappu R.V., Tompa P., Uversky V.N., Wright P.E., Babu M.M. Classification of intrinsically disordered regions and proteins. Chem. Rev. 2014, 114:6589-6631.
66. Wang W., Ye W., Jiang C., Luo R., Chen H.F. New force field on modeling intrinsically disordered proteins. Chem. Biol. Drug Des. 2014, 84:253-269.
67. Wang X., Crowe P.J., Goldstein D., Yang J.L. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int. J. Oncol. 2012, 41:1181-1191.
68. Wanner J., Fry D.C., Peng Z., Roberts J. Druggability assessment of protein-protein interfaces. Future Med. Chem. 2011, 3:2021-2038.
69. Wilson B.G., Roberts C.W.M. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 2011, 11:481-492.
70. Wright P.E., Dyson H.J. Linking folding and binding. Curr. Opin. Struct. Biol. 2009, 19:31-38.
71. Wright P.E., Dyson H.J. Intrinsically disordered proteins in cellular signalling and regulation. Nat. Rev. Mol. Cell. Biol. 2015, 16:18-29.
72. Yeh J.E., Toniolo P.A., Frank D.A. Targeting transcription factors: promising new strategies for cancer therapy. Curr. Opin. Oncol. 2013, 25:652-658.
73. Yu H., Lee H., Herrmann A., Buettner R., Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 2014, 14:736-746.
74. Zhang M., Catrow J.L., Ji H. High-throughput selectivity assays for small-molecule inhibitors of beta-Catenin/T-cell factor protein-protein interactions. ACS Med. Chem. Lett. 2013, 4:306-311.
75. Zhang Q., Tang X., Lu Q., Zhang Z., Rao J., Le A.D. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1α protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol. Cancer Ther. 2006, 5:1227-1238.
76. Zhang Q., Tang X., Lu Q.Y., Zhang Z.F., Brown J., Le A.D. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol. Cancer Ther. 2005, 4:1465-1474.
77. Zinzalla G., Thurston D.E. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Med. Chem. 2009, 1:65-93.